01—Abstract
Summary
Summary of the 8-K/A filed March 23, 2026. Cited figures are marked; the original filing is the authoritative source.
Roivant Sciences Ltd. (ROIV) has filed Amendment No. 1 on Form 8-K/A to its Current Report originally filed March 3, 2026.
The sole purpose of this amendment is to file the Settlement Agreement, dated March 3, 2026, as Exhibit 10.1, as the Original 8-K had said a copy would be filed later. No other changes are made to the Original 8-K. The Settlement Agreement is among Genevant Sciences GmbH, a Roivant subsidiary, Arbutus Biopharma Corp., and, solely for certain purposes, Genevant Sciences Ltd., on one side, and Moderna, Inc. and ModernaTx, Inc. on the other.
It resolves all patent infringement litigation between Genevant/Arbutus and Moderna, pending in the U.S. and internationally, relating to Moderna's use of Genevant/Arbutus' lipid nanoparticle delivery technology in its vaccines. The filing states that portions of the exhibit have been omitted under Item 601(b)(10)(iv) of Regulation S-K because they are not material and are the type the Company treats as private or confidential, and that certain exhibits and schedules have been omitted under Item 601(a)(5). The filing does not disclose settlement payment terms in the text provided.
02—Key points
Key Highlights
- Amendment No. 1 on Form 8-K/A files the full Settlement Agreement, dated March 3, 2026, as Exhibit 10.1, completing a disclosure promised in the Original 8-K.
- The Settlement Agreement resolves all patent infringement litigation between Genevant/Arbutus and Moderna, pending in the U.S. and internationally.
- The litigation concerned Moderna's use of Genevant/Arbutus' lipid nanoparticle delivery technology in its vaccines.
- Genevant Sciences GmbH, a Roivant subsidiary, is a party to the Settlement Agreement alongside Arbutus Biopharma Corp.
- Genevant Sciences Ltd. is a party solely for certain purposes.
- Certain portions of the exhibit were omitted as not material and as the type the Company treats as private or confidential.
- Certain exhibits and schedules were omitted under Item 601(a)(5) of Regulation S-K.
03—Questions
Frequently Asked Questions
What does this 8-K/A filing change from the original 8-K?
Nothing in the substance of the original disclosure changes. The amendment only attaches the Settlement Agreement dated March 3, 2026, as Exhibit 10.1, which the Original 8-K said would be filed later.
Which parties are involved in the settlement?
The parties are Genevant Sciences GmbH, a Roivant subsidiary, and Arbutus Biopharma Corp., together with Genevant Sciences Ltd. solely for certain purposes, on one side, and Moderna, Inc. and ModernaTx, Inc. on the other.
What dispute does the settlement resolve?
It resolves all pending patent infringement litigation between Genevant/Arbutus and Moderna, in the U.S. and internationally, over Moderna's use of Genevant/Arbutus' lipid nanoparticle delivery technology in its vaccines.
Are the settlement terms fully public?
Not entirely. Certain portions of the exhibit were omitted as not material and as the type the Company treats as private or confidential, and certain exhibits and schedules were omitted under Item 601(a)(5) of Regulation S-K.
04—Continue